← All trials
NCT02304198
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2014
- Primary completion
- Feb 1, 2016
- Completion date
- Feb 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 59
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Dong-A PharmaceuticalLead sponsor
- Sungkyunkwan UniversityOverall official - principal investigator
- Catholic University of KoreaOverall official - principal investigator
- Yonsei UniversityOverall official - principal investigator
- Chungnam National UniversityOverall official - principal investigator
- Chonbuk National UniversityOverall official - principal investigator
- Seoul National UniversityOverall official - principal investigator
- Sungkyunkwan UniversityStudy chair
- University of UlsanOverall official - principal investigator
- Chonnam National UniversityOverall official - principal investigator
- Pusan National UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.